In Q1 FY2026 (ended March 31, 2026), Monte Rosa Therapeutics reported revenue of $4.21 million, a 95% decline year-over-year, reflecting the absence of significant collaboration revenue. Net loss widened to $44.5 million, compared to a loss of $15.1 million in the prior-year quarter. Operating loss was $50.0 million, up 214% from $16.0 million. The company held $159.9 million in cash and $521.9 million in total equity, with no long-term debt.
•Revenue fell 95% YoY to $4.21M, likely due to the end of a major collaboration agreement.
•Net loss expanded to $44.5M from $15.1M, driven by higher operating expenses.
•Operating loss increased 214% to $50.0M, reflecting increased R&D and SG&A costs.
•Cash position of $159.9M and no debt provide runway for ongoing operations.
Informational summary based on SEC XBRL figures · generated by deepseek-v4-flash. Not investment advice.
Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company develops novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins.
The company develops orally bioavailable molecular glue degraders (MGDs), such as MRT-2359 for the treatment of MYC-driven tumors. Its portfolio also includes MRT-6160 for the treatment of neurologic and systemic autoimmune and inflammatory diseases, and MRT-8102 for the treatment of inflammatory diseases driven by IL-1a, IL-1ß and IL-18
Damage-associated molecular patterns. Additionally, it develops CDK2 to treat multiple cancers, including ovarian, endometrial, gastric and breast. Further, its pipeline includes programs in immunology and inflammation indications, oncology, cardiovascular, metabolic, and genetic diseases. It also develops QuEEN, a discovery engine, to enable its target-centric MGD discovery and development approach and its rational design of MGD product candidates.
It has a strategic collaboration and licensing agreement with F. Hoffmann-La Roche Ltd.; and Novartis. Incorporated in 2019, the company is headquartered in Boston, Massachusetts.
Monte Rosa Therapeutics is a clinical-stage biotechnology company focused on developing novel small molecule precision medicines. The company's approach leverages the body's natural protein degradation mechanisms to selectively eliminate therapeutically relevant proteins. Its lead product candidate, MRT-2359, is being developed for the treatment of MYC-driven tumors. Additionally, the pipeline includes MRT-6160 for neurologic and systemic autoimmune and inflammatory diseases, and MRT-8102 for inflammatory diseases driven by IL-1a, IL-1ß, and IL-18. The company also has a CDK2 program targeting multiple cancers such as ovarian, endometrial, gastric, and breast cancers. Monte Rosa's discovery engine, QuEEN, enables rational design of molecular glue degraders (MGDs) across various therapeutic areas including oncology, immunology, cardiovascular, metabolic, and genetic diseases.
Where is Monte Rosa Therapeutics (GLUE) listed and in what currency?
Monte Rosa Therapeutics is listed on the Nasdaq Global Select Market (NasdaqGS) under the ticker symbol GLUE. The company's shares are traded in US Dollars (USD), which is the currency of its primary listing exchange. The NasdaqGS is a major US stock exchange that hosts many biotechnology and technology companies. Investors can buy and sell GLUE shares during regular trading hours on Nasdaq, and the stock price is quoted in USD. The company's financial reports and filings are also denominated in US Dollars, reflecting its operations based in the United States.
What sector and industry does Monte Rosa Therapeutics (GLUE) belong to?
Monte Rosa Therapeutics operates in the Healthcare sector, specifically within the Biotechnology industry. As a clinical-stage biotechnology company, it is engaged in the research and development of innovative therapies that target disease at the molecular level. The biotechnology industry is characterized by high research and development costs, long development timelines, and significant regulatory oversight. Monte Rosa's focus on molecular glue degraders (MGDs) places it at the forefront of targeted protein degradation, a cutting-edge approach in drug discovery. The company's work spans multiple therapeutic areas, including oncology, immunology, and inflammatory diseases, which are key focus areas within the broader healthcare sector.
Where is Monte Rosa Therapeutics (GLUE) headquartered and what is its history?
Monte Rosa Therapeutics is headquartered in Boston, Massachusetts, United States. The company was incorporated in 2019, making it a relatively young player in the biotechnology space. Boston is a major hub for biotechnology and pharmaceutical research, providing access to a rich ecosystem of academic institutions, research hospitals, and skilled talent. Since its founding, Monte Rosa has built a robust pipeline of molecular glue degraders and established strategic collaborations with industry leaders such as F. Hoffmann-La Roche Ltd. and Novartis. The company's location in Boston supports its mission to develop precision medicines that address significant unmet medical needs across oncology, immunology, and other diseases.
What is the business model of Monte Rosa Therapeutics (GLUE) and how does it generate value?
Monte Rosa Therapeutics operates as a clinical-stage biotechnology company, meaning it does not yet have approved products on the market and currently generates no product revenue. Its business model centers on discovering and developing novel molecular glue degraders (MGDs) through its proprietary QuEEN discovery engine. The company aims to create value by advancing its pipeline of drug candidates through preclinical and clinical development, with the goal of eventually obtaining regulatory approval and commercializing therapies. To support its research and development efforts, Monte Rosa has entered into strategic collaboration and licensing agreements with major pharmaceutical companies like F. Hoffmann-La Roche Ltd. and Novartis. These partnerships may provide upfront payments, milestone payments, and royalties, which are typical revenue sources for clinical-stage biotech firms. The company's portfolio includes candidates targeting oncology (e.g., MRT-2359, CDK2), immunology and inflammation (e.g., MRT-6160, MRT-8102), as well as programs in cardiovascular, metabolic, and genetic diseases.